Lewes, DE -- (SBWIRE) -- 10/01/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: XUMANII INTERNATION(OTCMKTS:XUII), TGFIN Holdings Inc.(OTCMKTS:TGFN), Generex Biotechnology Corporation (OTCMKTS:GNBT), Safer Shot, Inc.(OTCMKTS:SAFS)
XUMANII INTERNATION(OTCMKTS:XUII) opened at the price of $0.02, along with 830,578.00 shares outstanding and touched its highest price of the day at $0.03 recently. The stock is trading at the price of $0.0246 by scoring +8.85% at 12:56PM.
The stock’s previous performance of one month showed that it lost almost -52.69%. In the previous 3 months it dropped +93.01%. Xumanii International Holdings Corp provides online live content streaming services through its Website, xumanii.com. It also offers an embedded player for placing on other Websites for streaming, as well as Xumanii-Facebook application to enable the producer?s viral marketing promotion for their events.
What was the Moving Force behind XUII On Bullish Run? Read This Research Report on XUII
TGFIN Holdings Inc.(OTCMKTS:TGFN) stock recently hit highest its price at $0.03, starting its day trade with a price of $0.03 and reported an increase of 3.70%. Its most recent trading price was $0.0280 at 12:42 PM. 52 week price range of the company is $0.03 - $0.03, while today, up until :12:42PM, its minimum price was $0.03. TGFIN Holdings, Inc., a development stage company, develops software applications for the Apple iphone and other hand-held devices in the United States. Its applications include SportsCast Baseball, SportsCast Basketball, and SportsCast Soccer. The company sells its applications online at the Apple Store. TGFIN Holdings, Inc. is based in Smithfield, Utah.
For How Long TGFN will Fight for Profitability? Read This Trend Analysis report
Generex Biotechnology Corporation (OTCMKTS:GNBT) remained among the bears of the day during the early hours of trading, as it went down -6.80% recently. Beta value of the stock remained at 1.90 points, while its earnings per share was -$0.02.
During the last 5 day’s it declined -3.96%, while its last one month’s performance stands at - 1.56%. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Why Should Investors Buy GNBT After theRecentFall? Just Go Here and Find Out
Safer Shot, Inc.(OTCMKTS:SAFS) is trading with a fall of -45.20% along with the exchange price of $0.0274 up till now while its introductory price for today was $0.09.
Company’s 6 month’s performance gave a bright outlook/diminishing overview as it gained 226.19%. while in its last 5 days its performance remained in the green/red with the/plummet/ improvement of -46.27%. Safer Shot, Inc., a development stage company, focuses on purchasing patents for a less than lethal weapon. It intends to develop Bouncer, a less than lethal weapon. The company was formerly known as Monumental Marketing, Inc. and changed its name to Safer Shot, Inc. in January 2008. Safer Shot, Inc. was founded in 1997 and is based in Salt Lake City, Utah.
Will SAFS Get Buyers Even After The Recent Rally? Find Out Here
About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/